Company Focus
Vertex Pharmaceuticals
Latest Vertex Pharmaceuticals News
Pharmaceutical
Vertex Pharmaceuticals missed Wall Street estimates for the first quarter of 2025, as sales of its cystic fibrosis (CF) therapy Trikafta (elexacaftor/tezacaftor/ivacaftor) came in lower than expected. 6 May 2025
Related News
Insights
Company Spotlight
An American biotech company developing solutions that treat urothelial and specialty cancers.
Latest News & Features of interest to Vertex Pharmaceuticals
Biotechnology
UK pharma major GSK yesterday announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. 23 May 2025
Biotechnology
The US Food and Drug Administration (FDA) has approved Roche’s(ROG: SIX) Susvimo (ranibizumab injection) 100mg/mL for the treatment of diabetic retinopathy (DR), a potentially blinding condition that affects almost 10 million people in the USA and more than 100 million people globally. 23 May 2025
Pharmaceutical
USA-based nonprofit CureDuchenne has announced the appointment of Brenda Wong as its new chief medical advisor (CMA), effective January 5, 2026. 22 May 2025
Biotechnology
This week on The Pharma Letter Podcast, we’re joined by Quin Wills, co-founder and chief scientific officer of UK biotech Ochre Bio. 22 May 2025
Pharmaceutical
USA-based UroGen Pharma, a biotech developing and commercializing innovative solutions that treat urothelial and specialty cancers, closed 45% lower Wednesday. 22 May 2025
Pharmaceutical
Pharmasyntez, one of Russia’s leading drugmakers, plans a significant expansion of its portfolio of innovative drugs in the short-term, according to recent statements, made by representatives of the company, reports The Pharma Letter’s local correspondent. 21 May 2025
Pharmaceutical
UK-based PureTech Health delivered a late-breaking, oral presentation at the 2025 American Thoracic Society (ATS) International Conference in San Francisco. 21 May 2025
Pharmaceutical
US biotech Tourmaline Bio has reported topline data from a Phase II trial of its lead asset, pacibekitug, in people with chronic kidney disease (CKD) and elevated inflammation levels associated with cardiovascular risk. 21 May 2025
Pharmaceutical
US healthcare giant Johnson & Johnson presented long-term findings from the 24-month open-label extension of the A DUE trial of Opsynvi (macitentan and tadalafil) in pulmonary arterial hypertension (PAH) during a late-breaking oral session at the American Thoracic Society (ATS) Conference. 21 May 2025
Biotechnology
Shares in Prime Medicine, a US biotech seeking to develop one-time curative genetic therapies, closed 16% lower Monday. 20 May 2025
Latest In Brief for Vertex Pharmaceuticals
Pharmaceutical
Novo Nordisk’s two-year suspension from the Association of the British Pharmaceutical Industry (ABPI) for serious breaches of the ABPI Code of Practice has come to an end. 17 March 2025
Latest Relevant Ones To Watch News
California’s BioMarin Pharmaceutical is to acquire Inozyme Pharma or $4 per share in an all-cash transaction for a total consideration of approximately $270 million. 16 May 2025
30 April 2025
28 April 2025
24 March 2025
20 March 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze